The article considers the problem of determination of organ clearance and the time course of drug plasma concentration using the model for which the drug transit time through the organ is regarded as one of the parameters. The suggested nonsteady state approach to the determination of organ clearance conceptually corresponds to the parallel tube model, and directly takes into account the delay of drug exit from the organ due to the transit time tau. The considered model is linear, so that the definition of mean organ clearance as D(o)/AUC, where D(o) is the quantity of drug eliminated by the organ and AUC is the area under drug plasma concentration time curve, is relevant and yields the same value as obtained at steady state. The plasma concentration-time profile for a two-compartmental model (blood-organ) with the account of transit time tau is found. It is a piece-continuous function, which includes exponential and polynomial terms. The considered model provides a better understanding in which situation the account of transit time through the organ may influence pharmacokinetic profiles. The unique feature of the model is that it predicts the possibility of the oscillating drug plasma concentration-time curves following iv bolus dose due to the initial fast distribution of drug into the organs. This could explain the secondary peaks or humps of drug plasma concentration profiles sometimes observed at the early time points after iv bolus injection for compounds that do not undergo hepatic recirculation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/jps.21715 | DOI Listing |
PLoS One
January 2025
Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.
Aflatoxin B1 (AFB1) is a class 1 carcinogen and mycotoxin known to contribute to the development of hepatocellular carcinoma (HCC), growth impairment, altered immune system modulation, and malnutrition. AFB1 is synthesized by Aspergillus flavus and is known to widely contaminate foodstuffs, particularly maize, wheat, and groundnuts. The mechanism in which AFB1 causes genetic mutations has been well studied, however its metabolomic effects remained largely unknown.
View Article and Find Full Text PDFPLoS One
January 2025
Facultad de Farmacia y Bioquímica, Departamento de Ciencias Biológicas, Cátedra de Biología Celular y Molecular, Universidad de Buenos Aires, Buenos Aires, Argentina.
Chronic kidney disease (CKD) is one of the leading health problems in the world. It is silent in the early stages and gradually progresses, inducing renal physiological and structural alterations. Moreover, CKD is associated with impaired life quality, increased risk for cardiovascular diseases, and reduced life expectancy.
View Article and Find Full Text PDFRheumatology (Oxford)
January 2025
Division of Nephrology, Nanfang Hospital, Southern Medical University; National Clinical Research Center for Kidney Disease; State Key Laboratory of Organ Failure Research; Guangdong Provincial Institute of Nephrology, Guangdong Provincial Key Laboratory of Renal Failure Research, Guangdong Laboratory, Guangzhou, 510515, China.
Objectives: The relationship between proteomic profiles and incident systemic lupus erythematosus (SLE) remains unclear. We aimed to identify candidate plasma proteins for SLE risk in women, discover potential treatment targets for SLE, and develop and validate a protein-based prediction model for SLE risk.
Methods: 28 220 women from the UK Biobank were randomly split into training (70%) and testing (30%) sets.
J Pharm Pharmacol
January 2025
Department of Biochemistry, State University of Maringá, 87020900, PR, Brazil.
Objectives: Copaiba essential oil (CEO) is obtained through the distillation of copaiba balsam and has been used in the traditional medicine to treat inflammatory conditions. However, the highly lipophilic nature of CEO restricts its pharmaceutical use. This study evaluated the effect of CEO, carried in a self-nanoemulsifying drug delivery system (SNEDDS), on articular and systemic inflammation and liver changes in Holtzman rats with Freund's adjuvant-induced arthritis.
View Article and Find Full Text PDFTher Drug Monit
January 2025
School of Pharmaceutical Sciences, Hangzhou First People's Hospital, Zhejiang Chinese Medical University, Hangzhou, China.
Background: Nirmatrelvir/ritonavir is licensed for the treatment of mild-to-moderate coronavirus disease (COVID-19) in patients at an increased risk of progression to severe disease. However, data on the real-world plasma exposure to nirmatrelvir/ritonavir remain limited, particularly in Chinese patients. This study aimed to assess the nirmatrelvir/ritonavir trough concentration (Ctrough) and identify its critical factors in hospitalized Chinese patients treated with nirmatrelvir/ritonavir 300 mg/100 mg twice daily over a 5-day course.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!